A SIX-MONTH, OPEN-LABEL, CROSSOVER STUDY OF THE MAINTENANCE OF SERUM TESTOSTERONE AND PSA SUPPRESSION AFTER SWITCHING BETWEEN LUPRON 22.5 MG AND ELIGARD 22.5 MG OR ZOLADEX 10.8 MG AND ELIGARD 22.5 MG IN PATIENTS WITH ADVANCED PROSTATE CANCER: